164 related articles for article (PubMed ID: 21528523)
21. Active surveillance for clinically localized prostate cancer--a systematic review.
Thomsen FB; Brasso K; Klotz LH; Røder MA; Berg KD; Iversen P
J Surg Oncol; 2014 Jun; 109(8):830-5. PubMed ID: 24610744
[TBL] [Abstract][Full Text] [Related]
22. [Active surveillance for screen-detected prostate cancer - a strategy for the future?].
Weissbach L; Schaefer C
Aktuelle Urol; 2010 Jul; 41(4):239-44. PubMed ID: 20661840
[TBL] [Abstract][Full Text] [Related]
23. The role of 5-alpha-reductase inhibitors in active surveillance.
Margel D; Fleshner N
Curr Opin Urol; 2012 May; 22(3):243-6. PubMed ID: 22472511
[TBL] [Abstract][Full Text] [Related]
24. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer: epidemiology and health-related quality of life.
Penson DF; Rossignol M; Sartor AO; Scardino PT; Abenhaim LL
Urology; 2008 Dec; 72(6 Suppl):S3-11. PubMed ID: 19095126
[TBL] [Abstract][Full Text] [Related]
26. Overdiagnosis and overtreatment of early detected prostate cancer.
Bangma CH; Roemeling S; Schröder FH
World J Urol; 2007 Mar; 25(1):3-9. PubMed ID: 17364211
[TBL] [Abstract][Full Text] [Related]
27. Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other.
Klotz L; Polascik TJ
Oncology (Williston Park); 2014 Nov; 28(11):950-C3. PubMed ID: 25741545
[No Abstract] [Full Text] [Related]
28. [Active surveillance for localized prostate cancer].
Staerman F; Peyromaure M; Irani J; Gaschignard N; Mottet N; Soulié M; Salomon L;
Prog Urol; 2011 Jul; 21(7):448-54. PubMed ID: 21693354
[TBL] [Abstract][Full Text] [Related]
29. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
[TBL] [Abstract][Full Text] [Related]
30. Critical review: is watchful waiting a viable management option for older men with prostate cancer?
Bailey DE; Wallace M
Am J Mens Health; 2007 Mar; 1(1):18-28. PubMed ID: 19482780
[TBL] [Abstract][Full Text] [Related]
31. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
32. Active surveillance for prostate cancer in a veteran population.
Lee EK; Baack J; Penn H; Bromfield CT; Duchene DA; Thrasher JB; Holzbeierlein JM
Can J Urol; 2010 Dec; 17(6):5429-35. PubMed ID: 21172105
[TBL] [Abstract][Full Text] [Related]
33. Active surveillance for low-risk prostate cancer.
Mazzucchelli R; Nesseris I; Cheng L; Lopez-Beltran A; Montironi R; Scarpelli M
Anticancer Res; 2010 Sep; 30(9):3683-92. PubMed ID: 20944154
[TBL] [Abstract][Full Text] [Related]
34. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.
van den Bergh RC; Vasarainen H; van der Poel HG; Vis-Maters JJ; Rietbergen JB; Pickles T; Cornel EB; Valdagni R; Jaspars JJ; van der Hoeven J; Staerman F; Oomens EH; Rannikko A; Roemeling S; Steyerberg EW; Roobol MJ; Schröder FH; Bangma CH
BJU Int; 2010 Apr; 105(7):956-62. PubMed ID: 19817747
[TBL] [Abstract][Full Text] [Related]
35. Outcomes and follow-up strategies for patients on active surveillance.
Dall'Era MA; Carroll PR
Curr Opin Urol; 2009 May; 19(3):258-62. PubMed ID: 19295434
[TBL] [Abstract][Full Text] [Related]
36. [Criticisms to patient selection in active surveillance in prostate cancer].
Gomez Veiga F; Portela Pereira P; Vazquez-Martul Pazos D; Pertega Diaz S; Martinez Breijo S; Mendez Diaz C; Rodríguez E
Arch Esp Urol; 2014 Jun; 67(5):495-508. PubMed ID: 24914849
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer.
Holmberg L; Bill-Axelson A; Helgesen F; Salo JO; Folmerz P; Häggman M; Andersson SO; Spångberg A; Busch C; Nordling S; Palmgren J; Adami HO; Johansson JE; Norlén BJ;
N Engl J Med; 2002 Sep; 347(11):781-9. PubMed ID: 12226148
[TBL] [Abstract][Full Text] [Related]
38. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
39. Maximizing outcomes in genitourinary cancers across the treatment continuum.
Fitzpatrick JM; Bellmunt J; Dreicer R; Fleshner NE; Logothetis CJ; Moul JW; Tombal B; Zlotta A
BJU Int; 2011 Apr; 107 Suppl 2():1-12. PubMed ID: 21382149
[TBL] [Abstract][Full Text] [Related]
40. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
Bartoletti R; Cai T
Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
